| Actemra IV (tocilizumab) / Roche, JW Pharma |
| Ongoing | 4 | 180 | Europe | MabThera, RoActemra, L01X CO2, L04AC07, Concentrate for solution for infusion, MabThera, RoActemra | Joint Research & Development Office (Barts and The London School of Medicine & Dentistry), Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, , Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, ECAM Clinical Academic Group Barts Health NHS Trust, Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2010-018696-21: Etude de l’évolution de la réponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoïde et traités par tocilizumab après échec des autres thérapies |
|
|
| Ongoing | 4 | 15 | Europe | TOCILIZUMAB, RoACTEMRA, RoACTEMRA | CHU DIJON | Polyarthrite rhumatoïde | | | | |
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas |
|
|
| Ongoing | 4 | 28 | Europe | Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra | FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA | Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas | | | | |
ChiCTR-OPC-17011391: The efficacy and safety of tocilizumab for refractory systemic juvenile idiopathic arthritis in China |
|
|
| Completed | 4 | 60 | | tocilizumab ;glucocorticoid | Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University, Chongqing Science and Technology Commission | systemic juvenile idiopathic arthritis | | | | |
2015-000833-64: Comparaison de trois biomédicaments en termes d’évolution des sous-populations lymphocytaires régulatrices et pro-inflammatoires chez des patients atteints de polyarthrite rhumatoïde. |
|
|
| Not yet recruiting | 4 | 110 | Europe | Powder for concentrate for solution for injection/infusion, Solution for infusion, ORENCIA, MABTHERA, ROACTEMRA | CHU Amiens-Picardie | Rheumatoid arthritis polyarthrite rhumatoïde, Rheumatoid arthritis Polyarthrite rhumatoïde, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-001970-41: Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial |
|
|
| Ongoing | 4 | 180 | Europe | Abatacept, Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, L04AA24, L04AB04, L04AB05, L04AB01, L04AB06, L04AB02, L04AC07, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Concentrate and solvent for solution for injection, Concentrate and solvent for suspension for injection, Orencia, Humira, Cimzia, Enbrel, Benepali, Simponi, Remsima, Remicade, RoActemra, Inflectra, Imraldi, Amgevita | MD, PhD Salome Kristensen, The Danish Regions (Regionernes Medicinpulje), The Department of Rheumatology at Aalborg University Hospital, Health Science Research Fund of the Region of Northern Jutland | Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (arthritis of the spine), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Not yet recruiting | 4 | 18 | | Tocilizumab treatment group | Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital; Peking Union Medical College Hospital, “863” Project of Ministry of Science and Technology | Takayasu's arteritis | | | | |
ChiCTR1800015472: A single arm,single-center clinical study of tocilizumab in the treatment of corticosteroids unresponsive pre-engraftment syndrome patients after unrelated cord blood transplantation |
|
|
| Recruiting | 4 | 10 | | Tocilizumab | Anhui Provincial Hospital; Anhui Provincial Hospital, National Natural Science Foundation of China | hematologic malignancies patients with PES after umbilical cord blood transplantation | | | | |
2017-003037-28: Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs. |
|
|
| Not yet recruiting | 4 | 120 | Europe | Prednisone, Solution for injection/infusion in pre-filled syringe, Tablet, RoActemra, Prednisone | University Medical Center Utrecht, University Medical Center Utrecht, Roche | RA patients with active RA despite treatment with DMARDs. Reumatoïde artritis, RA patients with active RA despite treatment with DMARDs. Reuma (reumatoïde artritis), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment |
|
|
| Not yet recruiting | 4 | 84 | Europe | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara | Reade, ZonMw | rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
ChiCTR2000033705: A medical records based study for the preliminary efficacy of Tocilizumab in the treatment of the patients with novel coronavirus pneumonia (COVID-19) |
|
|
| Completed | 4 | 61 | | Tocilizumab ;routine treatment protocol | Xijing Hospital; Xijing Hospital, the Key Research and Development Project of Shaanxi Province of China (grant number 2020ZDXM-SF-002) and Natural Science Foundation of Shaanxi Province of China (grant number 2019JM-465). | Novel Coronavirus Pneumonia (COVID-19) | | | | |
2020-001437-12: Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs ENSAYO CLÍNICO ALEATORIZADO, CONTROLADO, ABIERTO, UNICÉNTRICO, DE TRATAMIENTO INMUNOMODULADOR EN PACIENTES ADULTOS CON NEUMONIA GRAVE COVID-19 |
|
|
| Ongoing | 4 | 290 | Europe | RoActemra, Concentrate for solution for infusion, Capsule, soft, Sandimmun, RoActemra | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | Severe COVID-19 pneumonia Neumonía grave COVID-19, Severe COVID-19 pneumonia Neumonía grave COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR2000029765: A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | 4 | 188 | | conventional therapy ;conventional therapy+tocilizumab | The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital), Department of science and technology of Anhui Province | new coronavirus pneumonia | | | | |
ChiCTR2000030894: Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial |
|
|
| Recruiting | 4 | 150 | | Favipiravir Combined With Tocilizumab ;Favipiravir ;Tocilizumab | Peking University First Hospital; Peking University First Hospital, self-financed | Novel Coronavirus Pneumonia (COVID-19) | | | | |
2019-004302-10: A clinical trial to study Tocilizumab for treatment of chronic rejection due to antibodies in kidney transplant patients |
|
|
| Not yet recruiting | 4 | 50 | Europe | Solution for injection in pre-filled pen, RoActemra | Västra Götalandsregionen, Sahlgrenska University hospital, Vetenskapsrådet | Treatment of chronic active antibody-mediated rejection in kidney transplant recipients, Treatment of chronic kidney transplant rejection due to antibodies, Body processes [G] - Immune system processes [G12] | | | | |
ChiCTR-OPB-17013704: A phase IV, multicenter single-arm, open-label study to assess the efficecy and safety of Tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis |
|
|
| Recruiting | 4 | 65 | | Tocilizumab | Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University, Drug clinical trial bid party (Shanghai Roche Pharmaceuticals Ltd.) | systemic juvenile idiopathic arthritis | | | | |
NCT04779047: Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. |
|
|
| Recruiting | 4 | 150 | RoW | Remdesivir, Hydroxychloroquine, Tocilizumab, Actemra, Lopinavir/ Ritonavir, kaletra, Ivermectin, Iverazine | October 6 University, Beni-Suef University | Covid19, Pneumonia | 03/21 | 04/21 | | |
| Recruiting | 4 | 98 | Europe | Tocilizumab | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development | Rheumatoid Arthritis | 12/24 | 12/24 | | |
ADDORA-switch, NCT04251741: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment |
|
|
| Active, not recruiting | 4 | 86 | Europe | Adalimumab trough concentration, Usual care | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 05/24 | 05/24 | | |
NCT04300686: A Pilot Study in Severe Patients With Takayasu Arteritis. |
|
|
| Recruiting | 4 | 40 | RoW | Tocilizumab, IL-6R alpha antibody, Adalimumab, TNF-alpha antibody | Shanghai Zhongshan Hospital | Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment | 05/22 | 12/23 | | |
ChiCTR2000032678: A multicenter, non-interventional, prospective study of the safety and efficacy of tocilizumab in the treatment of rheumatoid arthritis in the real world |
|
|
| Not yet recruiting | 4 | 2500 | | N/A | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shanghai Roche Pharmaceutical Co., Ltd. | RA | | | | |
NCT04762784: A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis |
|
|
| Recruiting | 4 | 40 | RoW | Tocilizumab, Glucocorticoids | Peking Union Medical College Hospital | Idiopathic Retroperitoneal Fibrosis | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 812 | Europe, RoW | Non-biological DMARD's, Cimzia, Orencia, RoActemra | Karolinska Institutet | Rheumatoid Arthritis | 07/23 | 12/23 | | |
NCT05730777: Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics |
|
|
| Not yet recruiting | 4 | 200 | RoW | Bifidobacterium Bifidum Oral Capsule, Probiotics, Cisplatin, conventional antitumor treatmen, Carboplatin, Paclitaxel, Atlizumab | Peking University Third Hospital | Cancer Therapy-related Cardiovascular Toxicity | 07/23 | 12/23 | | |
| Active, not recruiting | 4 | 25 | Europe | Sulphasalazine + Hydroxychloroquine OR Prednisolone, SSZ+HCQ or Prednisolone, Cimzia, Certolizumab-pegol, Orencia, Abatacept, RoActemra, Tocilizumab | Karolinska Institutet | Rheumatoid Arthritis | 07/23 | 12/23 | | |
ChiCTR2100044103: Epirubicin-loaded microspheres TACE combined with tocilizumab in the treatment of stage III hepatocellular carcinoma |
|
|
| Recruiting | 4 | 156 | | DEB-TACE ;DEB-TACE combined with IL-6 antibody | Qingdao University Affiliated Hospital; Qilu Hospital of Shandong University, Beijing Medical Award Foundation | Primary liver cancer | | | | |
NCT05604859: Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) |
|
|
| Recruiting | 4 | 350 | RoW | Methylprednisolone, intravenous immunoglobulin, Tocilizumab, Low molecular weight heparin, conventional treatment | Qin Ning | Severe Fever With Thrombocytopenia Syndrome | 12/23 | 06/24 | | |
NCT06498089: A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes With a Conventional Treatment Regimen in the Treatment of Patients With Active Takayasu's Arteritis |
|
|
| Recruiting | 4 | 124 | RoW | Prednisone, Glucocorticoids, Methotrexate, MTX, Cyclophosphamid, CYC, Tocilizumab, TCZ, Tofacitinib, TOF, Rituximab, RTX | Shanghai Zhongshan Hospital | Takayasu Arteritis | 06/26 | 06/27 | | |
NCT05855122: Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients |
|
|
| Recruiting | 4 | 48 | RoW | Tocilizumab | The First Affiliated Hospital of Soochow University | Multiple Myeloma | 08/24 | 12/24 | | |
NCT06251076: Plan Development for Giving Teclistamab in the Outpatient Setting |
|
|
| Not yet recruiting | 4 | 15 | NA | Teclistamab, TECVAYLI, Tocilizumab, ACTEMRA | University Health Network, Toronto, Janssen Inc. | Multiple Myeloma, Relapsed Cancer, Refractory Cancer | 04/25 | 09/25 | | |
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide |
|
|
| Recruiting | 4 | 286 | Europe | Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration | University Hospital, Strasbourg, France | Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide | 03/25 | 03/25 | | |
